{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:24:33Z","timestamp":1793413473939,"version":"4.5.0"},"reference-count":41,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2019,4,3]]},"DOI":"10.1080\/21645515.2018.1549449","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T11:02:03Z","timestamp":1542711723000},"page":"809-821","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and\n            <i>Haemophilus influenzae<\/i>\n            type b vaccine: a randomized trial in the United States"],"prefix":"10.1080","volume":"15","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remon","family":"Abu-Elyazeed","sequence":"additional","affiliation":[{"name":"GSK, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Cheuvart","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Janssens","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narcisa","family":"Mesaros","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1044180"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777x.77298"},{"key":"e_1_3_7_4_1","unstructured":"Food and Drug Administration. PEDIARIX [Diphtheria and tetanus toxoids and acellular pertussis adsorbed Hepatitis B (Recombinant) and inactivated poliovirus vaccine]. 2002 [accessed 2018 Feb 16]. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM241874.pdf."},{"key":"e_1_3_7_5_1","article-title":"Pentacel (Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)","author":"Food and Drug Administration","year":"2008","unstructured":"Food and Drug Administration. Pentacel (Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate). Vaccine. 2008 [[accessed 2018 Feb 16]. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm109810.pdf.","journal-title":"Vaccine"},{"key":"e_1_3_7_6_1","unstructured":"Food and Drug Administration. ENGERIX-B [Hepatitis B Vaccine (Recombinant)]. 1989 [accessed 2018 Feb 16]. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm224503.pdf."},{"key":"e_1_3_7_7_1","unstructured":"Food and Drug Administration. ActHIB\u00ae Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate). 1993 [accessed 2018 Feb 16]. https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm109841.pdf."},{"issue":"36","key":"e_1_3_7_8_1","first-page":"1008","article-title":"Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","unstructured":"Centers for Disease Control and Prevention. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep. 2009. 58(36)1008\u20131009.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6516a3"},{"key":"e_1_3_7_10_1","unstructured":"European Medicines Agency. Infarix hexa. Summary of Product Characteristics. 2000 [accessed 2018 Apr 30]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000296\/WC500032505.pdf."},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1419070"},{"key":"e_1_3_7_12_1","volume-title":"4th World Congress of the World Society for Pediatric Infectious Diseases","author":"Black S","year":"2005","unstructured":"Black S, Nakasato C, Davis R, France E, Schuerman L, Jacquet JM, Friedland L Two large phase III, multicenter trials comparing primary vaccination with DTPa-HBV-IPV\/Hib versus commercially available vaccines administered at separate sites (abstract). 4th World Congress of the World Society for Pediatric Infectious Diseases; 2005; Warsaw, Poland."},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199804001-00834"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000160914.59160.41"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200850"},{"key":"e_1_3_7_16_1","unstructured":"Centers for Disease Control and Prevention. Pertussis (Whooping Cough). 2017 [accessed 2018 Feb 26]. https:\/\/www.cdc.gov\/pertussis\/outbreaks\/about.html."},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)04356-5"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410017572"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/514741"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199709000-00009"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.107796"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310050544"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.02.021"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/426396"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04377-9"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00517-X"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1383157"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(18)30166-x"},{"key":"e_1_3_7_29_1","unstructured":"GlaxoSmithKline Biologicals. Final study report for clinical trial 217744\/025 DTPa-HBV-IPV-025. 2005 [accessed 2018 Apr 30]. https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-217744-025-clinical-study-report-redact.pdf."},{"key":"e_1_3_7_30_1","unstructured":"GlaxoSmithKline Biologicals. Final Study Report DTPa-HBV-IPV-099. 2005 [accessed 2018 Apr 30]. https:\/\/www.gsk-clinicalstudyregister.com\/files2\/gsk-217744-099-clinical-study-report-redact.pdf."},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200525050-00004"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.044"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.008"},{"key":"e_1_3_7_34_1","unstructured":"Rotarix. GPm. 2018 [accessed 2018 Feb 23]. http:\/\/ca.gsk.com.gsk.idm.oclc.org\/media\/1216129\/rotarix.pdf."},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.20.4.772-774.1984"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-1157(83)80038-9"},{"key":"e_1_3_7_37_1","volume-title":"Standard procedure for determining immunity to poliovirus using the microneutralisation test (WHO\/EPI\/GEN 93.9)","author":"World Health Organisation (WHO)","year":"1993","unstructured":"World Health Organisation (WHO). Standard procedure for determining immunity to poliovirus using the microneutralisation test (WHO\/EPI\/GEN 93.9). 1993. Geneva: World Health Organization."},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/147.6.1100"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.6.1034"},{"issue":"13","key":"e_1_3_7_40_1","first-page":"1","article-title":"Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the immunisation practices advisory committee (ACIP)","volume":"40","author":"Centers for Disease Control and Prevention (CDC)","year":"1991","unstructured":"Centers for Disease Control and Prevention (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the immunisation practices advisory committee (ACIP). MMWR Recomm Rep. 1991. 40(RR\u201313)1\u201325.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"e_1_3_7_41_1","first-page":"443","article-title":"Progress in the control of viral hepatitis: memorandum for a WHO meeting","volume":"66","author":"World Health Organization (WHO)","year":"1988","unstructured":"World Health Organization (WHO). Progress in the control of viral hepatitis: memorandum for a WHO meeting. Bull World Health Organ. 1988. 66(4)443\u2013445.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tandfonline.com\/doi\/pdf\/10.1080\/21645515.2018.1549449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2018.1549449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T07:42:34Z","timestamp":1707896554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2018.1549449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,3]]}},"alternative-id":["10.1080\/21645515.2018.1549449"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2018.1549449","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}